Prohibitin promotes dedifferentiation and is a potential therapeutic target in neuroblastoma
Ian C. MacArthur(Albert Einstein College of Medicine), Anton G. Henssen(Charité - Universitätsmedizin Berlin)
Cited by 33
Related Papers
Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
|Molecular Cancer Therapeutics|2023|17
Passenger Gene Coamplifications Create Collateral Therapeutic Vulnerabilities in Cancer
|Cancer Discovery|2024|16
Purification and Sequencing of Large Circular DNA from Human Cells
|Protocol Exchange|2019|12
Elimusertib outperforms standard of care chemotherapy in preclinical patient-derived pediatric solid tumor models
|bioRxiv (Cold Spring Harbor Laboratory)|2022|3